Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experience
2006

Study of GAT Chemotherapy for Metastatic Breast Cancer

Sample size: 33 publication Evidence: moderate

Author Information

Author(s): Passardi Alessandro, Massa Ilaria, Zoli Wainer, Gianni Lorenzo, Milandri Carlo, Zumaglini Federica, Nanni Oriana, Maltoni Roberta, Frassineti Giovanni Luca, Amadori Dino

Primary Institution: Department of Medical Oncology, Morgagni-Pierantoni Hospital, Forlì, Italy

Hypothesis

Can the GAT regimen (gemcitabine, doxorubicin, and paclitaxel) be an effective first-line chemotherapy for metastatic breast cancer?

Conclusion

The GAT regimen is effective in treating anthracycline-naïve metastatic breast cancer and has manageable toxicity.

Supporting Evidence

  • The overall response rate was 55.2%, with complete responses in 6.9% and partial responses in 48.3% of patients.
  • The median time to progression was 10.2 months and overall survival was 36.4 months.
  • Hematological toxicity was the most significant, with grade III-IV neutropenia observed in 69% of patients.

Takeaway

This study tested a new combination of three cancer drugs to see if they work well together for women with advanced breast cancer, and they found it was effective.

Methodology

Patients with stage IIIB-IV breast cancer received a combination of gemcitabine, doxorubicin, and paclitaxel in a phase II trial.

Limitations

The study had a small sample size and was limited to patients who were anthracycline-naïve.

Participant Demographics

Median age was 59 years, with the majority being postmenopausal.

Statistical Information

P-Value

p<0.05

Confidence Interval

95 CI, 37.5% to 62.5%

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1471-2407-6-76

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication